AnnDoanBassMD

Neurology • San Antonio, TX

Neuroimmunology/Multiple Sclerosis

Neurology Center of San Antonio, PA

Join to view full profile

Dr. Bass is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bass' full profile

Already have an account?

Office
1314 E Sonterra Blvd
Suite 601
San Antonio, TX 78258
Phone+1 210-490-0016

Fax+1 210-490-3010

Summary

I am a board-certified neurologist specializing in the diagnosis, treatment, and management of multiple sclerosis and other CNS demyelinating diseases. I am the Medical Director of the comprehensive MS clinic at the Neurology Center of San Antonio, which is affiliated and certified by the National Multiple Sclerosis Society.

Clinical Expertise

Multiple sclerosis, Demyelinating diseases, Neuroimmunology (Multiple sclerosis)

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Neurology, 1994 - 1997
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineInternship, Internal Medicine, 1993 - 1994
The University of Texas Health Science Center at San AntonioClass of 1993

Certifications & Licensure

TX State Medical License 1995 - 2026
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Most Compassionate Doctor American Registry
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) Start of enrollment: 2019 Jul 22
Active, not recruiting
Roles: Principal Investigator
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. Start of enrollment: 2022 Jan 25
Active, not recruiting
Phase 4
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis Start of enrollment: 2022 May 03
Active, not recruiting
Phase 3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS Start of enrollment: 2018 Dec 28
Recruiting
Phase 3
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis Start of enrollment: 2018 May 28
Active, not recruiting
Phase 3
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) Start of enrollment: 2020 Jun 11
Active, not recruiting
Phase 3
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) Start of enrollment: 2020 Sep 24
Active, not recruiting
Phase 3
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) Start of enrollment: 2020 Aug 13
Recruiting
Phase 3
Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) Start of enrollment: 2020 Jan 16
Active, not recruiting
Phase 3
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis Start of enrollment: 2019 Nov 18
Active, not recruiting
Phase 3
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS) Start of enrollment: 2018 Sep 14
Completed
Phase 3
An Extension of the TG1101-RMS201 Trial Start of enrollment: 2017 Jun 01
Completed
Phase 2
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) Start of enrollment: 2017 Sep 19
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

37 citations
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Adam Cuker, Ann D Bass, Congor Nadj, Mark A Agius, Brian Steingo
Multiple Sclerosis. 2020-01-01
188 citations
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial
Alasdair Coles, Edward Fox, A. Vladic, Suzanne Gazda, Vesna V. Brinar
Neurology. 2012-04-03
21 citations
Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey.
Ann D Bass, Bart Van Wijmeersch, Lori Mayer, Mathias Mäurer, Aaron Boster
International Journal of MS Care. 2020-07-01

Abstracts/Posters

Efficacy of a fourth alemtuzumab course in RRMS patients from CARE-MS II who experienced disease activity after three prior courses
Traboulsee A, Alroughani R, Boster A, Bass A, Berkovich R, Fernandez O, Kim H-J, Limmroth V, Lycke J, Macdonell RAL, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Mela..., 53rd CNSF Congress 2018, Halifax, Nova Scotia, Canada, 6/24/2018
Efficacy of a Fourth Alemtuzumab Course in RRMS Patients With Disease Activity After Three Prior Courses: Analysis of CARE-MS I
Heinz Wiendl1, Raed Alroughani2, Aaron Boster3, Anthony Traboulsee4, Ann D Bass5, Regina Berkovich6, Giancarlo Comi7, Óscar Fernández8, Ho Jin Kim9, Volker Limmroth10,..., EAN 2018, Lisbon, Portugal, 6/16/2018
Efficacy of a Fourth Alemtuzumab Course in RRMS Patients With Disease Activity After Three Prior Courses: Analysis of CARE-MS II
Barry A Singer1, Raed Alroughani2, Aaron Boster3, Ann D Bass4, Regina Berkovich5, Giancarlo Comi6, Óscar Fernández7, Ho Jin Kim8, Volker Limmroth9, Jan Lycke10, Richar..., CMSC 2018, Nashville, TN, 5/30/2018
Efficacy of Alemtuzumab Retreatment After 2 Initial Courses
Basil Sharrack1, Barry A Singer2 Aaron Boster3, Ann D Bass4, Regina Berkovich5, Giancarlo Comi6, Óscar Fernández7, Ho Jin Kim8, Volker Limmroth9, Jan Lycke10, Richard ..., 2018 Annual Conference of the Association of British Neurologists (ABN), Birmingham, United Kingdom, 5/9/2018
Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: ...
Aaron Boster1, Ann D Bass2, Regina Berkovich3, Giancarlo Comi4, Óscar Fernández5, Ho Jin Kim6, Volker Limmroth7, Jan Lycke8, Richard AL Macdonell9, Basil Sharrack10, A..., AAN 2018, Los Angeles, CA, 4/21/2018
Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: ...
Barry A Singer1, Aaron Boster2, Ann D Bass3, Regina Berkovich4, Giancarlo Comi5, Óscar Fernández6, Ho Jin Kim7, Volker Limmroth8, Jan Lycke9, Richard AL Macdonell10, B..., AAN 2018, Los Angeles, CA, 4/21/2018
Efficacy of a Third Course of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Experienced Disease Activity After the Initial Two Courses...
Patrick Vermersch1, Anthony Traboulsee2, Aaron Boster3, Ann D Bass4, Regina Berkovich5, Giancarlo Comi6, Óscar Fernández7, Ho Jin Kim8, Volker Limmroth9, Jan Lycke10, ..., 12th World Congress on Controversies in Neurology (CONy), Warsaw, Poland, 3/22/2018
Efficacy of Alemtuzumab Retreatment in Patients Who Experienced Disease Activity After the Initial Two Courses: Results from CARE-MS II
Aaron Boster1, Anthony Traboulsee2, Ann D Bass3, Regina Berkovich4, Giancarlo Comi5, Óscar Fernández6, Ho Jin Kim7, Volker Limmroth8, Jan Lycke9, Richard AL Macdonell1..., ACTRIMS 2018, San Diego, CA, 2/1/2018
Efficacy of a Third Course of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Experienced Disease Activity After the Initial Two Courses...
Kim H-J, Traboulsee A, Boster A, Bass A, Berkovich R, Comi G, Fernandez O, Limmroth V, Lycke J, Macdonell RAL, Sharrack B, Vermersch P, Wiendl H, Ziemssen T, Melanson ..., PACTRIMS 2017, Ho Chi Minh City, Vietnam, 11/23/2017
Efficacy of a Third Course of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Experienced Disease Activity After the Initial Two Courses...
Anthony Traboulsee, Aaron Boster, Ann D Bass, Regina Berkovich, Giancarlo Comi, Óscar Fernández, Ho Jin Kim, Volker Limmroth, Jan Lycke, Richard AL Macdonell, Basil Sh..., ECTRIMS 2017, Paris, France, 10/25/2017
Efficacy and Safety of Alemtuzumab in Patients With RRMS Is Durable Over 10 Years: Follow-up From the CAMMS223 Study
Krzysztof W Selmaj, Mario Habek, Ann Bass, David Brassat, Vesna Brinar, Alasdair J Coles, Anton Vladic, Sibyl E Wray, David H Margolin, Karthinathan Thangavelu, Madali..., AAN 2017, Boston, MA, 4/22/2017
Impact of Multiple Sclerosis on Patients’ Daily Activities, Emotional Well-Being and Relationships: Results of the Global vsMS™ Survey
Ann Bass, Bart Van Wijmeersch, Lori Mayer, Mathias Mäurer, Matt Mandel, Kersten Sharrock, Barry Singer, AAN 2017, Boston, MA, 4/22/2017
Join now to see all

Press Mentions

Merck Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022March 31st, 2022
EMD Serono Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022March 31st, 2022
Woman Learns to Embrace Life with Relapsing Multiple Sclerosis (MS)May 29th, 2019
Join now to see all